Glioblastoma remains one of the deadliest brain cancers, but select academic centers now offer personalized immunotherapy through clinical trial enrollment—treatments tailored to individual tumor biology rather than one-size-fits-all chemotherapy. Eligibility depends on molecular markers, performance status, and post-surgical timing. This guide explains which centers offer these protocols, what criteria determine candidacy, and how evaluation services help navigate trial acce